Evidence map›Paper›PMID 39810812›Full record

ArticleIDCases2025

Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient.

Sarah Sakalihasan, Frédéric Lifrange, Mathieu Czajkowski, Veronique Goncette, Bernard Duysinx, Pierre Lovinfosse, Damla Can, Raphael Schils, Marie-Pierre Hayette, Adrien De Voeght

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah SakalihasanDepartment of Medicine, Division of Hematology, CHU of Liège, Liège 4000, Belgium.
Frédéric LifrangeDepartment of Pathology, University Hospital Center of Liege, Liege, Belgium.
Mathieu CzajkowskiService d'ORL, d'audiophonologie et de chir. cervico-faciale, University Hospital Center of Liege, Liege, Belgium.
Veronique GoncetteDepartment of Hospital Pharmacy, University Hospital of Liège, Liège, Belgium.
Bernard DuysinxDivision of Pulmonology, University Hospital of Liège, Liège, Belgium.
Pierre LovinfosseDivision of Nuclear Medicine and Oncological Imaging, University Hospital of Liège, University of Liège (ULiège), Liège, Belgium.
Damla CanDivision of Radiology, University Hospital of Liège, Liège, Belgium.
Raphael SchilsDepartment of Medicine, Division of Internal Medicine and Infectious Diseases, University of Liege, Liege, Belgium.
Marie-Pierre HayetteDepartment of Clinical Microbiology, University Hospital of Liege, Liege 4000, Belgium.
Adrien De VoeghtGroupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), Laboratory of Hematology, University of Liège, Liège, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bispecific antibody is a new treatment for hematological disease, especially for lymphoma, myeloma and acute lymphoblastic leukemia. This class of treatment presents the same kind of side effect as CAR-T cell which are immune-mediated. Nevertheless, infectious complication remains a major concerns with related mortality. Fungal infection are rarely reported in clinical trial but remains a major concern. We report a case of a co-infection of

Indexed as

AerosolCase reportImmunocompromised patientMycotic bi-therapy

Identifiers

PMID39810812
PMCPMC11732460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.